Study of Comprehensive ANd Multimodal Marker-based Cohort of Progressive Supranuclear Palsy(PSP)

Last updated: October 11, 2022
Sponsor: Seoul National University Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Progressive Supranuclear Palsy

Treatment

N/A

Clinical Study ID

NCT05579301
SNUH_2022_0117
  • Ages 50-80
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this cohort study is to develop a reliable biomarker in progressive nuclear palsy (PSP).

Eligibility Criteria

Inclusion

Inclusion Criteria for the patient group:

  • Age 50 to 80 years, male or female

  • Progressive supranuclear palsy (PSP) patients who are diagnosed as Probable, Possible or suggestive PSP with Movement Disorder society diagnostic criteria for PSP (Hoglinger et al., 2017)

Exclusion Criteria for the patient group:

  • Subjects with clinically significant psychiatric illness

  • Subjects with cancer or severe medical illness

  • Lactating, pregnant, or possibly pregnant

  • Subjects with small vessel disease (> grade II) in brain MRI or other structural lesions by causes other than PSP

  • Subjects with severe dementia patients (MMSE < 19 or MoCA <13 or General deterioration scale >= 5)

Inclusion Criteria for the healthy control group:

  • Age 50 to 80 years, male or female

  • Those who agreed to participate in this study

Exclusion Criteria for the healthy control group:

  • Those with a history of any neurological diseases

  • Lactating, pregnant, or possibly pregnant

  • Subjects with clinically significant psychiatric illness

  • Subjects with cancer or severe medical illness

Study Design

Total Participants: 130
Study Start date:
December 19, 2021
Estimated Completion Date:
February 28, 2025

Study Description

Progressive supranuclear palsy is a rapidly progressive neurodegenerative disease without a cure. Thus, the development of a biomarker that reflects and monitors disease severity in PSP is critical for early diagnosis and performing a successful clinical trial. Thus, we will prospectively recruit patients with PSP and collect comprehensive clinical, imaging and blood biomarkers at baseline with longitudinal follow-up for 1 year.

Connect with a study center

  • Seoul National University Boramae Hospital

    Seoul,
    Korea, Republic of

    Active - Recruiting

  • Seoul National University Hospital

    Seoul,
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.